| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Short Communication |
1 Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA
2 Institute for Antiviral Research, Animal, Dairy, and Veterinary Sciences Department and Biotechnology Center, Utah State University, Logan, UT 84322-4700, USA
3 Chengdu Jinniu Institute, Food Bureau of Sichuan Province, Chengdu Sichuan, China
Correspondence
David A. Kocisko
DKocisko{at}niaid.nih.gov
In vitro inhibitors of the accumulation of abnormal (protease-resistant) prion protein (PrP-res) can sometimes prolong the lives of scrapie-infected rodents. Here, transgenic mice were used to test the in vivo anti-scrapie activities of new PrP-res inhibitors, which, because they are approved drugs or edible natural products, might be considered for clinical trials in humans or livestock with transmissible spongiform encephalopathies (TSEs). These inhibitors were amodiaquine, thioridazine, thiothixene, trifluoperazine, tetrandrine, tannic acid and polyphenolic extracts of tea, grape seed and pine bark. Test compounds were administered for several weeks beginning 1–2 weeks prior to, or 2 weeks after, intracerebral or intraperitoneal 263K scrapie challenge. Tannic acid was also tested by direct preincubation with inoculum. None of the compounds significantly prolonged the scrapie incubation periods. These results highlight the need to assess TSE inhibitors active in cell culture against TSE infections in vivo prior to testing these compounds in humans and livestock.
This article has been cited by other articles:
|
|
 |
|
  S. Mouillet-Richard, N. Nishida, E. Pradines, H. Laude, B. Schneider, C. Feraudet, J. Grassi, J.-M. Launay, S. Lehmann, and O. Kellermann Prions Impair Bioaminergic Functions through Serotonin- or Catecholamine-derived Neurotoxins in Neuronal Cells J. Biol. Chem., August 29, 2008; 283(35): 23782 - 23790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brown Transmissible spongiform encephalopathy in the 21st century: Neuroscience for the clinical neurologist Neurology, February 26, 2008; 70(9): 713 - 722. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Riemer, M. Burwinkel, A. Schwarz, S. Gultner, S. W. F. Mok, I. Heise, N. Holtkamp, and M. Baier Evaluation of drugs for treatment of prion infections of the central nervous system J. Gen. Virol., February 1, 2008; 89(2): 594 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R Trevitt and J. Collinge A systematic review of prion therapeutics in experimental models Brain, September 1, 2006; 129(9): 2241 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C.H. May, C. Govaerts, and F. E. Cohen Developing therapeutics for the diseases of protein misfolding Neurology, January 24, 2006; 66(1_suppl_1): S118 - S122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kocisko and B. Caughey Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo J. Virol., January 15, 2006; 80(2): 1044 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Bertsch, K. F. Winklhofer, T. Hirschberger, J. Bieschke, P. Weber, F. U. Hartl, P. Tavan, J. Tatzelt, H. A. Kretzschmar, and A. Giese Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets J. Virol., June 15, 2005; 79(12): 7785 - 7791. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
